Humulin M3

Humulin M3 is a recombinant human insulin (Insulin Human, rDNA) marketed under the brand name Humulin M3. It is supplied as a subcutaneous injectable preparation, with the strength not disclosed in the data. Classified as an antidiabetic drug (ATC code A10AB01), it is prescribed by professionals for the management of blood glucose in diabetes mellitus. The product is authorized for use in the European Union and requires a prescription.

Humulin M3 is indicated for the treatment of diabetes mellitus when basal insulin coverage is required. It may be used in both type 1 and type 2 diabetes as part of a comprehensive glycemic control plan. - Initiation of insulin therapy in adults with type 1 diabetes. - Supplemental basal insulin for adults with type 2 diabetes inadequately controlled with oral agents. - Management of fasting and between‑meal glucose levels. - Use in combination with rapid‑acting insulin analogues for intensive regimens. - Adjusted dosing during periods of illness, stress, or changes in physical activity.

Adverse reactions to Humulin M3 may vary in frequency and severity. Reported events are grouped below for reference. Common: - Hypoglycemia, presenting as sweating, tremor, confusion, or loss of consciousness. - Injection‑site pain, redness, or swelling at the administration site. - Lipodystrophy, including localized fat accumulation (lipohypertrophy) or loss (lipoatrophy). - Moderate weight gain associated with improved glycemic control. - Mild nausea, abdominal discomfort, or transient gastrointestinal upset. Serious: - Severe hypoglycemia with neuroglycopenic symptoms such as seizures or coma. - Allergic reactions ranging from urticaria and angioedema to anaphylactic shock. - Fluid retention, peripheral edema, or worsening of congestive heart failure. - Development of insulin antibodies that may diminish therapeutic effect. - Respiratory distress or bronchospasm as part of a severe hypersensitivity response.

When prescribing Humulin M3, clinicians should consider several precautionary measures to ensure safe and effective use. - Assess renal and hepatic function before initiation and periodically during therapy. - Adjust dose in patients with impaired kidney function or fluctuating glucose levels. - Monitor for signs of hypoglycemia, especially in the elderly, children, or those with irregular meals. - Use caution in pregnancy and lactation; benefits must outweigh potential risks. - Evaluate cardiovascular status, as fluid retention may exacerbate heart failure. - Educate patients on proper injection technique to reduce lipodystrophy risk. - Review concomitant medications that may mask hypoglycemia symptoms.

Humulin M3 can interact with other agents that affect glucose metabolism or insulin action. The following combinations should be managed carefully. Avoid: - Concurrent use of other rapid‑acting insulin analogues without dose adjustment. - Beta‑blockers that may mask hypoglycemia symptoms. - High‑dose corticosteroids that increase insulin resistance. - MAO inhibitors, as they may interfere with carbohydrate metabolism. Use with caution: - Oral antidiabetic agents such as sulfonylureas or meglitinides, which can potentiate hypoglycemia. - Diuretics that may alter electrolyte balance and affect insulin requirements. - Alcohol consumption, which can cause unpredictable glucose fluctuations. - Thyroid hormones, which can increase basal metabolic rate and alter insulin needs.